Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.

Cao S, Durrani FA, Tóth K, Rustum YM.

Br J Cancer. 2014 Apr 2;110(7):1733-43. doi: 10.1038/bjc.2014.85. Epub 2014 Mar 11.


Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

Cao S, Durrani FA, Rustum YM, Yu YE.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1107-11. doi: 10.1007/s00280-011-1820-8. Epub 2012 Jan 12.


Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.

Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6.


Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M.

Oral Oncol. 2011 Jun;47(6):459-66. doi: 10.1016/j.oraloncology.2011.04.001. Epub 2011 May 6.


Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

Chintala S, Tóth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM.

Chemotherapy. 2010;56(3):223-33. doi: 10.1159/000316334. Epub 2010 Jun 11.


Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

Rustum YM, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A.

J Oncol. 2010;2010:396286. doi: 10.1155/2010/396286. Epub 2010 Apr 27.


Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.

Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. doi: 10.1007/s00280-009-1238-8. Epub 2010 Jan 12.


Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM.

Clin Colorectal Cancer. 2009 Jul;8(3):155-62. doi: 10.3816/CCC.2009.n.025.


Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.

Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM.

Clin Cancer Res. 2007 Feb 1;13(3):965-71.


Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF Jr, Prey J, Smith PF, Rustum YM.

Biochem Pharmacol. 2007 May 1;73(9):1280-7. Epub 2006 Dec 22.


Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

Cao S, Bhattacharya A, Durrani FA, Fakih M.

Expert Opin Pharmacother. 2006 Apr;7(6):687-703. Review.


Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.

Mol Cancer Ther. 2005 May;4(5):843-54.


Synergistic antitumor activity of capecitabine in combination with irinotecan.

Cao S, Durrani FA, Rustum YM.

Clin Colorectal Cancer. 2005 Jan;4(5):336-43.


Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.

Antony S, Kohlhagen G, Agama K, Jayaraman M, Cao S, Durrani FA, Rustum YM, Cushman M, Pommier Y.

Mol Pharmacol. 2005 Feb;67(2):523-30. Epub 2004 Nov 5.


Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.

Clin Cancer Res. 2004 Feb 1;10(3):1121-9.


Supplemental Content

Loading ...
Support Center